Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F McLeod

Showing results (41-50 of 66) with videos related to

Pageof 7
Sort By:
Cellular Immunology|August 1, 1977
Anti-MIF activity of serum from a rabbit immunized with human B-lymphoid cell line migration inhibitory factorT F McLeod, B L Baskin, S K Meltz, et al.
Cancer|December 1, 1987
Fatal bleomycin toxicity from a low cumulative dose in a patient with renal insufficiencyB F McLeod, H J Lawrence, D W Smith, et al.
Endocrinology|May 1, 1987
Detection of vitamin D binding protein on the surface of cytotrophoblasts isolated from human placentaeJ E Nestler, J F McLeod, M A Kowalski, et al.
Anesthesiology|September 16, 2014
Two studies on reversal of opioid-induced respiratory depression by BK-channel blocker GAL021 in human volunteersMargot Roozekrans, Rutger van der Schrier, Pieter Okkerse, et al.
The Journal of Clinical Endocrinology and Metabolism|September 1, 1993
Familial neurohypophyseal diabetes insipidus associated with a signal peptide mutationJ F McLeod, L Kovács, M B Gaskill, et al.
Journal of Clinical Pharmacology|March 6, 2003
Pharmacokinetics of nateglinide in renally impaired diabetic patientsDamayanthi Devineni, Yulia H Walter, Harold T Smith, et al.
British Journal of Clinical Pharmacology|January 3, 2001
Population PK and PK/PD modelling of microencapsulated octreotide acetate in healthy subjectsH Zhou, T L Chen, M Marino, et al.
Journal of Clinical Pharmacology|October 5, 2001
The effects of tegaserod (HTF 919) on the pharmacokinetics and pharmacodynamics of digoxin in healthy subjectsH Zhou, A Horowitz, P C Ledford, et al.
British Journal of Anaesthesia|July 4, 2014
GAL-021, a new intravenous BKCa-channel blocker, is well tolerated and stimulates ventilation in healthy volunteersJ F McLeod, J M Leempoels, S X Peng, et al.
Journal of Clinical Pharmacology|September 3, 1999
Effect of meal timing not critical for the pharmacokinetics of tegaserod (HTF 919)H Zhou, S Khalilieh, H Lau, et al.
Pageof 7

Showing results (41-50 of 66) with videos related to

Sort By:
Pageof 7
Cellular Immunology|August 1, 1977
Anti-MIF activity of serum from a rabbit immunized with human B-lymphoid cell line migration inhibitory factorT F McLeod, B L Baskin, S K Meltz, et al.
Cancer|December 1, 1987
Fatal bleomycin toxicity from a low cumulative dose in a patient with renal insufficiencyB F McLeod, H J Lawrence, D W Smith, et al.
Endocrinology|May 1, 1987
Detection of vitamin D binding protein on the surface of cytotrophoblasts isolated from human placentaeJ E Nestler, J F McLeod, M A Kowalski, et al.
Anesthesiology|September 16, 2014
Two studies on reversal of opioid-induced respiratory depression by BK-channel blocker GAL021 in human volunteersMargot Roozekrans, Rutger van der Schrier, Pieter Okkerse, et al.
The Journal of Clinical Endocrinology and Metabolism|September 1, 1993
Familial neurohypophyseal diabetes insipidus associated with a signal peptide mutationJ F McLeod, L Kovács, M B Gaskill, et al.
Journal of Clinical Pharmacology|March 6, 2003
Pharmacokinetics of nateglinide in renally impaired diabetic patientsDamayanthi Devineni, Yulia H Walter, Harold T Smith, et al.
British Journal of Clinical Pharmacology|January 3, 2001
Population PK and PK/PD modelling of microencapsulated octreotide acetate in healthy subjectsH Zhou, T L Chen, M Marino, et al.
Journal of Clinical Pharmacology|October 5, 2001
The effects of tegaserod (HTF 919) on the pharmacokinetics and pharmacodynamics of digoxin in healthy subjectsH Zhou, A Horowitz, P C Ledford, et al.
British Journal of Anaesthesia|July 4, 2014
GAL-021, a new intravenous BKCa-channel blocker, is well tolerated and stimulates ventilation in healthy volunteersJ F McLeod, J M Leempoels, S X Peng, et al.
Journal of Clinical Pharmacology|September 3, 1999
Effect of meal timing not critical for the pharmacokinetics of tegaserod (HTF 919)H Zhou, S Khalilieh, H Lau, et al.
Pageof 7